Increasing scientific standards, independence and transparency in post-authorisation studies: The role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 7, 2012, Pages 690-696

  Blake, Kevin V ^a   deVries, Corinne S ^b   Arlett, Peter ^a   Kurz, Xavier ^a   Fitt, Henry ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

ENCePP; Guidelines; Independence; Medicines; Pharmacoepidemiology; Regulation; Standards; Transparency

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL STUDY; DATA BASE; FUNDING; MEDICAL DECISION MAKING; MEDICAL SOCIETY; METHODOLOGY; POST AUTHORIZATION STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; REGISTER; RESEARCH; STUDY DESIGN;

EID: 84863556829     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3281     Document Type: Article

References (34)

1. Blumenthal D. Academic-industrial relationships in the life sciences. N Engl J Med 2003; 349: 2452-2459.
2. de Vries F, van Staa TP, Leufkens HG. Proton pump inhibitors, fracture risk and selection bias: three studies, same database, two answers. Osteoporos Int 2011; 22(5): 1641-2.
3. Wysowski DK. Oral bisphosphonates and oesophageal cancer. BMJ 2010; 341: c4506.
4. Swaroop Vedula S, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009; 361: 1963-1971.
5. Taubes G, Mann CC. Epidemiology faces its limits. Science 1995; 269: 5221.
6. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6(R1). (1996. Accessed September 2011).
7. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. (Accessed July 2011).
8. International Society for Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practices (GPP). (2007. Accessed September 2011).
9. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 2007; 18(6): 800-10.
10. European Risk Management Strategy: 2008-2009 work programme adopted. (2008. Accessed July 2011).
11. International Society for Pharmacoepidemiology (ISPE).
12. International Society of Pharmacovigilance (ISOP).
13. European Federation of Pharmaceutical Industries and Associations (EFPIA).
14. ENCePP Research Resources Database. (Accessed October 2011).
15. ENCePP. The ENCePP Code of Conduct. (2010. Accessed October 2011).
16. ENCePP. Checklist for Study Protocols (Revision 1). (2011. Accessed October 2011).
17. ENCePP. ENCePP Guide on Methodological Standards in Pharmacoepidemiology. (2011. Accessed October 2011).
18. Electronic Register of Studies. (Accessed October 2011).
19. ENCePP Work Plan 2011-2012. (2010. Accessed October 2011).
20. ENCePP Response to: Communication from the Commission to the European Parliament, the Council, the Economic and Social Committee and the Committee of the Regions 'A comprehensive approach on personal data protection in the European Union'. (2011, Accessed October 2011).
21. ENCePP Response to: Concept paper of 9 February 2011 submitted for public consultation by the European Commission on the Revision of the 'Clinical Trials Directive' 2001/20/EC. (2011, Accessed August 2011).
22. ENCePP Working Group 1. Existing guidances. (2010, Accessed September 2011).
23. Krlea-Jeri K, Chan A-W, Dickersin K, et al. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). Br Med J 2005; 330: 956-8.
24. Loder E, Groves T, MacAuley D. Registration of observational studies. Br Med J 2010; 340: c950.
25. Vandenbroucke JP. Preregistration of epidemiologic studies: an ill-founded mix of ideas. Epidemiology 2010; 21(5): 619-620.
26. Chavers S, Fife D, Wacholtz M, Stang P, Berlin J. Registration of observational studies: perspectives from an industry-based epidemiology group. Pharmacoepidemiol Drug Saf 2011: 20; 1009-1013. DOI: 10.1002/pds.2221.
27. Schneeweiss S, Avorn J. Postmarketing studies of drug safety. A European initiative could help bring more transparency and rigour to pharmacoepidemiology. Br Med J 2011; 342: d342.
28. ENCePP Studies. (Accessed October 2011).
29. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. (2001. Accessed August 2011).
30. ENCePP. ENCePP considerations on the definition of non-interventional trials under the current legislative framework ("Clinical Trials Directive" 2001/20/EC). (2011. Accessed November 2011).
31. ENCePP. Minutes of ENCePP Workshop with Medical Journal Editors. (2011, Accessed October 2011).
32. Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 and Regulation (EC) No 1394/2007 on advanced therapy medicinal products. (2010. Accessed July 2011).
33. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. (2010. Accessed July 2011).
34. Blake KV, Prilla S, Biscaro M, et al. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf 2011: 20; 1021-1029. DOI: 10.1002/pds.2209.